Boule reports decreased net sales in Q2 2026
Adjusted operating profit decreased to MSEK 3.3, affected by geopolitical disturbance and new CEO took office.
See the latest news and media coverage for Boule. We track all announcements, press releases, and industry mentions in real time, all in one place.
Hematology and clinical chemistry diagnostics provider
boule.comLast updated
In short: Boule Diagnostics appointed Johan Folkunger as CEO in 2026 amid a 13.3% sales decline and significant organizational restructuring.
Adjusted operating profit decreased to MSEK 3.3, affected by geopolitical disturbance and new CEO took office.
He succeeds Simonetta Tumbiolo and starts June 22, 2026.
She takes office on June 1, 2026 to ensure continuity while the board recruits a permanent CEO.
The AGM approved 2025 financials, re-elected directors, and authorized share issuance.
17/07 Boule Diagnostics AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026 CI 17/07 Bourse de...
This article first appeared on GuruFocus. Release Date: July 17, 2026 For the complete transcript of the earnings call, please refer to the full earnings...
Boule Diagnostics AB ( (SE:BOUL) ) just unveiled an announcement.
The diagnostics company Boule Diagnostics has appointed Simonetta Tumbiolo, currently Chief Commercial Officer Diagnostic, as acting CEO from June 1.
Track Boule and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Boule and other trending companies.